Company Overview and News
ROUYN-NORANDA, QUÉBEC--(Marketwired - Jan. 30, 2018) - GLOBEX MINING ENTERPRISES INC. (TSX:GMX)(FRANKFURT:G1MN)(STUTTGART:G1MN)(BERLIN:G1MN)(MUNICH:G1MN)(XETRA:G1MN)(OTCQX:GLBXF) is pleased to report that despite the Christmas and New Year's break, Globex's December royalty payment from the Nyrstar NV Zinc Mine in Tennessee rose again to US$ 133,199 or CAD$ 170,109 based on an average zinc price of US$ 1.
Dual-listed (ASX and TSX) Chalice Gold Mines announced yesterday that it will pull out of a joint venture agreement with Pilbara explorer Red Hill Iron, having deemed the company’s results inadequate.
ROUYN-NORANDA, QUÉBEC--(Marketwired - Oct. 19, 2017) - MINING ENTERPRISES INC. (TSX:GMX)(FRANKFURT:G1MN)(STUTTGART:G1MN)(BERLIN:G1MN)(MUNICH:G1MN)(XETRA:G1MN)(OTCQX:GLBXF) is pleased to inform shareholders that it has received or had confirmation that it will collect the following payments:
LAVAL, CANADA--(Marketwired - July 12, 2017) - Typhoon Exploration Inc. (TSX VENTURE:TYP) has finalized his compilation and interpretation works on the Monexco property (100% interest), located about 30 kilometres North-East from the town of Chibougamau, inside the North Plan Territory.
Chalice Gold Mines Ltd (ASX:CHN, TSE:CXN) is commencing a A$7.5 million FY2018 exploration initiative to advance its high priority gold and base metal targets in Australia and Canada.
ROUYN-NORANDA, QUEBEC--(Marketwired - June 20, 2017) - GLOBEX MINING ENTERPRISES INC. (TSX:GMX)(FRANKFURT:G1MN)(STUTTGART:G1MN)(BERLIN:G1MN)(MUNICH:G1MN)(XETRA:G1MN)(OTCQX:GLBXF) is pleased to update shareholders regarding various optioned and royalty projects.
Oklo Resources (ASX:OKU) continued gold exploration success in Mali has attracted domestic and international institutional and sophisticated investors to an oversubscribed raising.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 22, 2017) - First Mining Finance Corp. ("First Mining" or the "Company") (TSX VENTURE:FF)(OTCQX:FFMGF)(FRANKFURT:FMG) is pleased to announce the release of an updated mineral resource estimate for its Cameron Gold Project ("Cameron" or the "Project") located near the town of Sioux Narrows in northwestern Ontario. First Mining acquired the Cameron Gold Project on June 9, 2016 pursuant to its acquisition of a subsidiary of Chalice Gold Mines Limited ("Chalice") that held the Project.
ROUYN-NORANDA, QUÉBEC--(Marketwired - March 13, 2017) - GLOBEX MINING ENTERPRISES INC. (TSX:GMX)(FRANKFURT:G1MN)(STUTTGART:G1MN)(BERLIN:G1MN)(MUNICH:G1MN)(XETRA:G1MN)(OTCQX:GLBXF) is pleased to report the results of a recent mineral resource estimate study by Chalice Gold Mines Limited (TSX:CXN)(ASX:CHN) announced in a March 7th, 2017 press release about Globex's Nordeau West gold deposit located in Vauquelin Township, Quebec.
Chalice Gold Mines (ASX:CHN; TSE:CXN) has revealed a maiden JORC resource of circa 1.34 million tonnes at 4.1 g/t gold for 176,500 ounces gold at its Nordeau West deposit in Quebec, Canada.
Oklo Resources (ASX:OKU) has a new substantial shareholder in Chalice Gold Mines (ASX:CHN), which obtained its 6.3% stake through on-market purchases.
2018-04-25 - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
2018-04-25 - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...